NASDAQ:SRNESorrento Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sorrento Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.05 +0.10 (+2.02 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$4.81Now: $5.05▼$5.0950-Day Range$2.27MA: $3.38▼$6.7652-Week Range$1.39Now: $5.05▼$10.00Volume14.93 million shsAverage Volume63.46 million shsMarket Capitalization$1.06 billionP/E RatioN/ADividend YieldN/ABeta2.69 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company also develops CD38 Directed chimeric antigen receptor T-cell therapy (CAR-T) for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; carcinoembryonic antigen CAR-T cell therapy for the treatment of liver metastases of pancreatic cancer; and various human antibodies. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSorrento Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, Sorrento Therapeutics has a potential upside of 355.4% from its current price of $5.05.Amount of Analyst CoverageSorrento Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesSorrento Therapeutics has received 539 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSorrento Therapeutics has received 336 “underperform” votes. (Add your “underperform” vote.)Community SentimentSorrento Therapeutics has received 61.60% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote “Outperform” if you believe SRNE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSorrento Therapeutics does not currently pay a dividend.Dividend GrowthSorrento Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sorrento Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $92,800.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Sorrento Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.18% of the stock of Sorrento Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sorrento Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sorrento Therapeutics is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sorrento Therapeutics is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSorrento Therapeutics has a P/B Ratio of 21.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.05 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRNE Previous Symbol CUSIPN/A CIK850261 Webwww.sorrentotherapeutics.com Phone858-203-4100Debt Debt-to-Equity Ratio4.59 Current Ratio0.55 Quick Ratio0.52Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$31.43 million Price / Sales33.69 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book21.04Profitability EPS (Most Recent Fiscal Year)($2.12) Net Income$-292,070,000.00 Net Margins-754.90% Return on Equity-638.51% Return on Assets-41.37%Miscellaneous Employees382 Outstanding Shares209,690,000Market Cap$1.06 billion Next Earnings Date6/3/2020 (Estimated) OptionableOptionable NASDAQ:SRNE Rates by TradingView Receive SRNE News and Ratings via Email Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions How has Sorrento Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Sorrento Therapeutics' stock was trading at $1.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SRNE stock has increased by 173.0% and is now trading at $5.05. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Sorrento Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sorrento Therapeutics. When is Sorrento Therapeutics' next earnings date? Sorrento Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, June 3rd 2020. View our earnings forecast for Sorrento Therapeutics. How were Sorrento Therapeutics' earnings last quarter? Sorrento Therapeutics Inc (NASDAQ:SRNE) announced its earnings results on Monday, March, 2nd. The biopharmaceutical company reported ($0.41) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.41). The biopharmaceutical company earned $13.03 million during the quarter, compared to analysts' expectations of $7 million. Sorrento Therapeutics had a negative return on equity of 638.51% and a negative net margin of 754.90%. View Sorrento Therapeutics' earnings history. What price target have analysts set for SRNE? 3 brokerages have issued 1 year price objectives for Sorrento Therapeutics' shares. Their forecasts range from $21.00 to $24.00. On average, they anticipate Sorrento Therapeutics' stock price to reach $23.00 in the next year. This suggests a possible upside of 355.4% from the stock's current price. View analysts' price targets for Sorrento Therapeutics. Has Sorrento Therapeutics been receiving favorable news coverage? Media stories about SRNE stock have been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sorrento Therapeutics earned a news impact score of -1.1 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutSorrento Therapeutics. Who are some of Sorrento Therapeutics' key competitors? Some companies that are related to Sorrento Therapeutics include Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA), bluebird bio (BLUE), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Novavax (NVAX), Fate Therapeutics (FATE), Alector (ALEC), Bill.com (RVMD), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), SpringWorks Therapeutics (SWTX) and Editas Medicine (EDIT). View all competitors. What other stocks do shareholders of Sorrento Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Novavax (NVAX), Amarin (AMRN), Micron Technology (MU), AbbVie (ABBV) and Opko Health (OPK). Who are Sorrento Therapeutics' key executives? Sorrento Therapeutics' management team includes the following people: Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 55)Dr. Jerome Bernard Zeldis, Chief Medical Officer & Pres of Clinical Devel. (Age 69)Mr. George K. Ng, Corp. Sec. (Age 45)Mr. Jiong Shao M.B.A., CFA, Exec. VP & CFO (Age 51)Ms. Deborah H. Telman, Sr. VP & Gen. Counsel What is Sorrento Therapeutics' stock symbol? Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE." Who are Sorrento Therapeutics' major shareholders? Sorrento Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.85%), Cormorant Asset Management LP (2.38%), State Street Corp (1.27%), Geode Capital Management LLC (1.01%), Alliancebernstein L.P. (0.37%) and Nuveen Asset Management LLC (0.28%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd and Robin L Smith. View institutional ownership trends for Sorrento Therapeutics. Which major investors are selling Sorrento Therapeutics stock? SRNE stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Squarepoint Ops LLC, Wells Fargo & Company MN, UBS Group AG, Rathbone Brothers plc, Virtus ETF Advisers LLC, Invesco Ltd., and Legal & General Group Plc. View insider buying and selling activity for Sorrento Therapeutics. Which major investors are buying Sorrento Therapeutics stock? SRNE stock was bought by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Alliancebernstein L.P., JPMorgan Chase & Co., BlackRock Inc., Geode Capital Management LLC, SG Americas Securities LLC, Jane Street Group LLC, and AQR Capital Management LLC. View insider buying and selling activity for Sorrento Therapeutics. How do I buy shares of Sorrento Therapeutics? Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Sorrento Therapeutics' stock price today? One share of SRNE stock can currently be purchased for approximately $5.05. How big of a company is Sorrento Therapeutics? Sorrento Therapeutics has a market capitalization of $1.06 billion and generates $31.43 million in revenue each year. The biopharmaceutical company earns $-292,070,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Sorrento Therapeutics employs 382 workers across the globe. What is Sorrento Therapeutics' official website? The official website for Sorrento Therapeutics is www.sorrentotherapeutics.com. How can I contact Sorrento Therapeutics? Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
